Extremity Function After Transfemoral Transcatheter Aortic Valve Implantation: A TAVI XS Sub‐Study
Catheterization and Cardiovascular Interventions · 2026
DOI: 10.1002/ccd.70470 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2026. Verfasst von Geert A A Versteeg und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Femoral Artery, Transcatheter Aortic Valve Replacement, Catheterization, Peripheral. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medtronic Europe.
Abstract (Originalsprache)
Background
Physical decline after transcatheter aortic valve implantation (TAVI) is associated with worse outcomes. However, data on post‐TAVI extremity function are limited. This sub‐study of the TAVI XS trial aimed to assess extremity function after transfemoral TAVI, evaluate functional decline, compare outcomes between upper‐and lower‐extremity secondary access approaches and identify predictors of functional decline after TAVI.
Methods
The TAVI XS was a randomized clinical trial comparing upper‐ and lower‐extremity secondary access during TAVI. Patients were assessed for extremity function at baseline and at 30 days using the Lower Extremity Function Scale (higher score indicating better function) and the Quick Disabilities of the Arm, Shoulder, and Hand questionnaire (higher score indicating worse function).
Results
Lower‐extremity (45.0 [IQR 35.0–57.0] to 52.0 [39.0–63.0]; p < 0.001), and upper‐extremity function (11.4 [2.3–25.0] to 6.8 [0–22.7]; p = 0.003) improved after TAVI. Relevant decline in lower‐extremity function occurred in 20 (8.4%) patients, and in upper‐extremity function in 19 (8.0%) patients. No differences in post‐TAVI function were observed between upper‐ or lower‐extremity secondary access (lower‐extremity: 10.1% vs. 6.7%; p = 0.35, upper‐extremity: 7.6% vs. 8.4%; p = 0.81). Predictors (OR [95% CI]) of clinically relevant decline were baseline use of dual antiplatelet therapy/oral anticoagulants (4.17 [1.39–12.49]; p = 0.01) for lower‐extremity function and multiple punctures (4.05 [1.46–11.24]; p = 0.007) for upper‐extremity function. Age inversely affected lower‐ (0.92 [0.85–0.99/year]; p = 0.02) and upper‐extremity function (0.93 [0.86–0.99/year]; p = 0.04).
Conclusions
The incidence of clinically relevant decline in extremity function after TAVI is low. No differences in reported extremity function were observed between the upper‐ and lower‐extremity secondary access approach. Predictors of decline were antithrombotic therapy and multiple punctures. Trial Registration ClinicalTrials.gov identifier: NCT05672823.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Cardiology, Amsterdam UMC, Amsterdam, the Netherlands.
- Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
- Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
- Department of Medical Biosciences, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Cardiothoracic Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
ORCID-Profile: Geert A A Versteeg, Daniël C Overduin, Niels A Stens, Robert Jan van Geuns, Dick H J Thijssen, Niels van Royen
Förderung
- Medtronic Europe
Zitieren
APA
Versteeg, G. A. A., Rooijakkers, M. J. P., Hemelrijk, K. I., Vlaar, P. J., Overduin, D. C., van Wely, M. H., Aarts, H. M., van Ginkel, D. J., Stens, N. A., van Nunen, L. X., van Geuns, R. J., van Garsse, L. A. F. M., Geuzebroek, G. S. C., Verkroost, M. W. A., Cetinyurek-Yavuz, A., Heijmen, R. H., Thijssen, D. H. J., Ten Berg, J. M., Tonino, P. A. L., …, & van Royen, N. (2026). Extremity Function After Transfemoral Transcatheter Aortic Valve Implantation: A TAVI XS Sub‐Study. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70470
Vancouver
Versteeg GAA, Rooijakkers MJP, Hemelrijk KI, Vlaar PJ, Overduin DC, van Wely MH, et al. Extremity Function After Transfemoral Transcatheter Aortic Valve Implantation: A TAVI XS Sub‐Study. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70470
BibTeX
@article{Versteeg2026,
author = {Versteeg, Geert A A and Rooijakkers, Maxim J P and Hemelrijk, Kimberley I and Vlaar, Pieter J and Overduin, Daniël C and van Wely, Marleen H and Aarts, Hugo M and van Ginkel, Dirk-Jan and Stens, Niels A and van Nunen, Lokien X and van Geuns, Robert Jan and van Garsse, Leen A F M and Geuzebroek, Guillaume S C and Verkroost, Michel W A and Cetinyurek-Yavuz, Aysun and Heijmen, Robin H and Thijssen, Dick H J and Ten Berg, Jurrien M and Tonino, Pim A L and Delewi, Ronak and van Royen, Niels},
title = {Extremity Function After Transfemoral Transcatheter Aortic Valve Implantation: A TAVI XS Sub‐Study},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
doi = {10.1002/ccd.70470}
}
EUVIMED